Where on the Healthcare Continuum Should We Invest? The Case for Primary Care?

Heart Lung and Circulation

Volumn 18, Issue 2, 2009, Pages 108-113

  Tonkin, Andrew M ^a   Chen, Lei ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Cost effectiveness; Prevention; Risk

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE SYSTEM; HEALTH DISPARITY; HEALTH PROMOTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEDICARE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION;

AUSTRALIA; CORONARY DISEASE; FEMALE; HEALTH CARE REFORM; HUMANS; MALE; MYOCARDIAL INFARCTION; PRIMARY HEALTH CARE;

EID: 63249123222     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2008.11.008     Document Type: Article

References (30)

1. Begg S.J., Vos T., Barker B., Stanley L., and Lopez A.D. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 188 (2008) 36-40
2. Australian Institute of Health and Welfare. Health expenditure Australia 2006-07. Health and welfare expenditure series no. 35. Cat. no. HWE 42. Canberra: AIHW, 2008 (available at http://www.aihw.gov.au/publications/hwe/hea06-07/hea06-07.pdf; accessed December 2008).
3. Productivity Commission. Economic implications of an ageing Australia, research report. Canberra: Productivity Commission, 2005 (available at http://www.pc.gov.au/projects/study/ageing/docs/finalreport; accessed December 2008).
4. Bennett C. Beyond the blame game. Med J Aust 189 (2008) 31-32
5. Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., Giles W.H., and Capewell S. Explaining the decrease in U.S. deaths from coronary disease 1980-2000. N Engl J Med 356 (2007) 2388-2398
6. The shifting burden of cardiovascular disease in Australia. Report by Access Economics Pty. Ltd for the National Heart Foundation of Australia; 2005.
7. Tonkin A.M. Future challenges. In: Tonkin A.M. (Ed). Atherosclerosis and heart disease (2003), Martin Dunitz, London
8. Peeters A., Nusselder W., McNeil J., Moon L., Boyko E., and Tonkin A. Age-specific trends in cardiovascular mortality rates in Australia, the Netherlands and USA since 1980. Abstract presented to European Congress of Cardiology (2008)
9. Manuel D.G., Lim J., Tanuseputro P., Anderson G.M., Alter D.A., Laupacis A., and Mustard C.A. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 332 (2006) 659-662
10. Murray C.J.L., Lauer J.A., Hutubessy R.C.W., Niessen L., Tomijima N., Rodgers A., Lawes C.M.M., and Evans D.B. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361 (2003) 717-725
11. Jackson R., Barham P., Bills J., Birch T., McLennan L., MacMahon S., and Maling T. Management of raised blood pressure in New Zealand: a discussion document. BMJ 307 (1993) 107-110
12. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
13. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., National Heart, Lung, and and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
14. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington: New Zealand guidelines group, 2003 (available at http://www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf; accessed July 2008).
15. Tonkin A., Barter P., Best J., Boyden A., Furler J., Hossack K., Sullivan D., Thompson P., Vale M., Cooper C., Robinson M., and Clune E. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Position statement on lipid management-2005. Heart Lung Circ 14 (2005) 275-291
16. Australian Government Department of Health and Ageing. Pbs-eligibility criteria for lipid-lowering drugs. Canberra: DHA, 2006 (available at http://www.health.gov.au/internet/main/publishing.nsf/content/lipid_eligibilitycriteria.htm; accessed July 2008).
17. Chen L., Rogers S.L., Colagiuri S., Cadilhac D.A., Mathew T.H., Boyden A.N., Peeters A., Magliano D.J., Shaw J.E., Zimmet P.Z., and Tonkin A.M. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab study 1999-2000. Med J Aust 189 (2008) 319-322
18. Anderson K.M., Odell P.M., Wilson P.W.F., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 (1991) 293-298
19. Forge B.H., and Briganti E.M. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?. Med J Aust 175 (2001) 471-475
20. Bett J.H., Tonkin A.M., Thompson P.L., and Aroney C.N. Failure of current public educational campaigns to impact on the initial response of patients with possible heart attack. Int Med J 35 (2005) 279-282
21. Clark A.M., Hartling L., Vandermeer B., and McAlister F.A. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 143 (2005) 659-672
22. Daugherty S.L., Ho P.M., Spertus J.A., Jones P.G., Bach R.G., Krumholz H.M., Peterson E.D., Rumsfeld J.S., and Masoudi F.A. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med 168 (2008) 485-491
23. Chew D.P., Amerena J., Coverdale S., Rankin J., Astley C., and Brieger D. Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective audit. Intern Med J 37 (2007) 741-748
24. Reid C., Nelson M.R., Shiel L., Chew D., Connor G., and DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH registry. Heart Lung Circ 17 (2008) 114-118
25. Wald N., and Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1424
26. Choudhry N.K., Patrick A.R., Antman E.M., Avorn J., and Shrank W.H. Cost-effectiveness of providing full drug coverage to increase medication adherence in post myocardial infarction medicare beneficiaries. Circulation 117 (2008) 1261-1268
27. Britt H, Miller GC, Charles J, Bayram C, Pan Y, Henderson J, Valenti L, O'Halloran J, Harrison C, Fahridin S. General practice activity in Australia 2006-2007. General practice series no. 21. Cat. no. GEP 21. Canberra: Australian Institute of Health and Welfare, 2008.
28. Department of Health, United Kingdom. Economic modelling of vascular checks. London: Department of Health, UK, 2008 (available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085869; accessed December 2008).
29. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., Minhas R., Sheikh A., and Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336 (2008) 1475-1482
30. Carter R, Rankin B. Economic assessment of the NHFA proposal of a national CHD initiative in general practice. NHFA Research Report, December 2006.